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Abstract
Introduction The aim of this study was to examine IL-17A in
patients, following anti-TNF-α therapy and the effect of IL-17A
on matrix turnover and cartilage degradation.
Methods IL-17A expression was examined by ELISA and
immunohistology in the rheumatoid arthritis (RA) joints. RA
whole synovial tissue explant (RA ST), primary synovial
fibroblasts (RASFC), human cartilage and chondrocyte cultures
were stimulated with IL-17A +/- TNF-α and Oncostatin M
(OSM). Matrix metalloproteinase (MMP) and tissue inhibitor
(TIMP-1) were assessed by ELISA and zymography. Cartilage
proteoglycan release was assessed histologically by Safranin-O
staining. Clinical parameters, IL-17A, MMP/TIMP were
assessed in patients pre/post biologic therapy.
Results IL-17A levels were higher in RA vs osteoarthritis (OA)/
normal joints (P < 0.05). IL-17A up-regulated MMP-1, -2, -9, and
-13 in RA ST, RASFC, cartilage and chondrocyte cultures (P <
0.05). In combination with TNF-α and OSM, IL-17A shifted the
MMP:TIMP-1 ratio in favor of matrix degradation (all P < 0.05).
Cartilage proteoglycan depletion in response to IL-17A was
mild; however, in combination with TNF-α or OSM showed
almost complete proteoglycan depletion. Serum IL-17A was
detected in 28% of patients commencing biologic therapy. IL-
17A negative patients demonstrated reductions post therapy in
serum MMP1/TIMP4, MMP3/TIMP1 and MMP3/TIMP4 ratios
and an increase in CS846 (all P < 0.05). No significant changes
were observed in IL-17A positive patients.
Conclusions IL-17A is produced locally in the inflamed RA joint.
IL-17A promotes matrix turnover and cartilage destruction,
especially in the presence of other cytokines, mimicking the joint
environment. IL-17A levels are modulated in vivo, following anti-
TNF therapy, and may reflect changes in matrix turnover.
Introduction
Rheumatoid arthritis (RA) is a common autoimmune disease
characterised by proliferation of synovial tissue (ST) and joint
erosion [1]. Angiogenesis is an early, critical event enabling
lymphocytes and macrophages to enter the joint cavity by
active recruitment via the endothelium [2]. New vessels and
leukocyte migration lead to expansion of the ST into an
aggressive tumour-like pannus. The hyperplastic ST fibrob-
lasts (RASF) of the lining layer invade the cartilage causing
degradation via proteolytic cleavage of aggrecan and collagen
[3]. Cytokines and growth factors are required to stimulate cell
survival, proliferation and extracellular matrix (ECM) degrada-
tion as part of this process [4]. Cartilage and bone degrada-
tion is characterised by a loss of ECM through activation of
matrix metalloproteinases (MMPs) and decreased production
of specific tissue inhibitors such as tissue inhibitor of metallo-
A-SAA: acute serum-amyloid A; CRP: C-reactive protein; DAS28: 28-joint count Disease Activity Score; DMEM: Dulbecco's modified Eagle's 
medium; DPX: Dibutyl Phthlate Xylene; ECM: extracellular matrix; ELISA: enzyme-linked immunosorbent assay; EULAR: European League Against 
Rheumatism; FCS: fetal calf serum; H&E: haematoxylin and eosin; IG: immunoglobulin; IL: interleukin; MMP: matrix metalloproteinase; OA: osteoar-
thritis; OSM: oncostatin M; PBS: phosphate-buffered saline; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RASF: RA synovial fibroblasts; RASFC: 
primary synovial fibroblasts; SF: synovial fluid; SpA: Spondyloarthropathy; ST: synovial tissue; TGF: transforming growth factor; TIMP-1: tissue inhib-
itor of metalloproteinase 1; TNF: tumour necrosis factor.Arthritis Research & Therapy    Vol 11 No 4    Moran et al.
Page 2 of 12
(page number not for citation purposes)
proteinase 1 (TIMP-1) [5]. Joint destruction can be visualised
radiographically and is associated with long-term functional
disability [6,7]. Cartilage turnover can also be monitored by
measuring synthesis and degradation products of cartilage-
specific collagens and proteoglycans [8]. Recent studies by
our group and others have demonstrated that these collagen
biomarkers can be used to monitor disease activity and predict
radiographic outcome in patients with inflammatory arthritis
[9].
Targeted biologic therapies including anti-TNF-α have
advanced the treatment of inflammatory arthritis. Some
patients, however, do not respond, highlighting the need for
new therapeutic targets. The pro-inflammatory cytokine IL-17A
is one such potential target. IL-17A is the first identified mem-
ber of the IL-17 family (A to F), and it is most closely related to
IL17F with 50% sequence homology [10]. IL-17F demon-
strates similar but less potent effects to IL-17A [11]. The
recently identified subset of T helper cells termed Th17 cells
are the main source of IL-17A. However, CD8+ T cells, γδ T
cells and natural killer T cells can also secrete IL-17A. In both
the humans and mice, differentiation of naïve T cells into Th17
cells involves the cytokines transforming growth factor (TGF)-
β, IL-6, IL-21, IL-1β and IL-23 [12].
It has been shown previously, in RA ST from joint replacement
surgery, that IL-17A is spontaneously produced; also high lev-
els have been demonstrated in the synovial fluid (SF) of RA
patients. IL-17A has also been detected in SF from osteoar-
thritis (OA) patients; however, levels were lower than in RA SF
[13,14]. In vitro, IL-17A stimulates the production of cytokines
and chemokines including TNF-α, IL-1, IL-6 and IL-8 [15-17].
IL-17A also up-regulates MMP expression by chondrocytes
and synoviocytes resulting in cartilage damage [18,19] Fur-
thermore, IL-17A causes an upregulation in RANKL produc-
tion leading to bone erosion [20].
In animal studies in vivo a role for IL-17A has been established
in mediating cartilage and joint damage [21]. Injection of IL-
17A, alone, into naïve murine knee joints resulted in extensive
cartilage depletion and bone erosion [22]. Continuous admin-
istration of IL-17A by gene expression in mice significantly
increased inflammatory infiltrate, cartilage and joint erosion
[23]. Inhibition of IL-17A using blocking antibodies and a sol-
uble receptor in a mouse model or with IL-4 does protect
against inflammation and bone damage [24]. A role for IL-17A
in the progression of acute joint inflammation into chronic
destructive arthritis has also been demonstrated in an IL-17
receptor deficient (IL-17R-/-) mouse model [25]. These IL-
17R-/- mice showed suppressed joint inflammation and
impaired synovial expression of IL-1 and MMPs. A number of
studies have linked IL-17A producing Th17 cells to bone
destruction [13,26].
IL-17A appears to be associated with chronicity as demon-
strated by murine models of collagen-induced arthritis. IL-17A
was strongly dependent on TNF-α in the early stages of exper-
imental arthritis; however, at a later stage the disease became
IL-17A driven and both TNF-α and IL-1 independent [27].
Th17 cells were implicated in the erosive stage of chronic
arthritis independent of TNF-α [28]. In human RA peripheral
blood mononuclear cells the IL-17A/TNF-α ratio at baseline
was found to be lower in responders to anti-TNF therapy as
opposed to nonresponders [29]. This observation provides
further evidence for IL-17A having a role in disease chronicity
in human RA.
The aim of this study was to further examine the expression of
IL-17A in actively inflamed joints and to elucidate the mecha-
nism of IL-17A, alone and in combination with TNF-α and
oncostatin M (OSM) in matrix turnover and cartilage degrada-
tion using whole RA synovial tissue explants, primary synovial
fibroblasts (RASFC) and normal human cartilage cultures. Fur-
thermore, we examined the relation of IL-17A to matrix turnover
in patients following anti-TNF-α therapy.
Materials and methods
Synovial tissue, serum and synovial fluids
All patients fulfilled the 1987 American College of Rheumatol-
ogy criteria for a diagnosis of RA [30] and had actively
inflamed knee joints. RA ST was obtained at arthroscopy,
using local anaesthesia as previously described [31]. SF was
obtained from 49 patients with inflammatory arthritis (RA, n =
29; Spondyloarthropathy (SpA), n = 20) and five OA patients
by arthrocentesis and stored at -80°C. Paired serum was
obtained in 45 of 49 of these patients and serum from eight
healthy volunteer controls was obtained. Fully informed written
consent was obtained from each patient and the study was
approved by the St. Vincent's University Hospital Ethics and
Medical Research Committee.
Preparation of synovial tissue lysates
ST obtained at arthroscopy (RA, n = 11, psoriatic arthritis
(PsA), n = 12, OA, n = 3) were snap frozen in liquid nitrogen
and homogenised using a Mikro-Dismembrator (B. Braun Bio-
tech International, Allentown, Pennsylvania, USA). Homoge-
nised samples were resuspended in protein lysis buffer and
stored at -80°C. Protein concentration was determined by the
BCA protein assay (Pierce, Rockford, IL, USA).
Quantification of IL-17A protein levels
IL-17A protein expression was measured in serum, SF and ST
lysates by specific ELISA (R&D Systems Europe, Abingdon,
Oxon, United Kingdom). The ELISA standard curve range was
15 pg/ml to 1000 pg/ml. The lowest standard was used as the
detection limit. IL-17A expression in synovial tissue lysates
was corrected for total protein concentration.Available online http://arthritis-research.com/content/11/4/R113
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IL-17A Immunohistochemistry
Biopsy samples obtained at arthroscopy were embedded in
Tissue Tek medium and then snap-frozen and stored in liquid
nitrogen until sectioned for analysis. Serial 7 μM microtome
sections were mounted on Superfrost slides and fixed in ace-
tone for 10 minutes. The sections were then washed and
blocked with 1 × casein for 30 minutes. The sections were
then washed and incubated with 2 μg/ml goat polyclonal anti-
IL-17A (Santa Cruz, Heidelberg, Germany) or normal immu-
noglobulin (Ig) G2a control. After incubation for one hour at
room temperature and washing, the sections were incubated
with biotinylated mouse anti-goat IgG antibody for 30 minutes
at room temperature, followed by strepavidin-peroxidase com-
plex (Dako, Glostrup, Denmark) for 30 minutes and 3,3'-diami-
nobenzidine tetrahydrochloride for five minutes. Nuclear
counterstaining was performed using Mayer's haematoxylin,
the sections were then dehydrated, and mounted in Dibutyl
Phthlate Xylene (DPX). Sections from 11 RA and 3 OA
patients and healthy control tissue (n = 1) were analysed for
IL-17A synovium expression.
Primary fibroblast cell culture
RASFC were obtained by enzymatic digestion of synovial
biopsy specimens with 1 mg/ml of type 1 collagenase (Wor-
thington Biochemical, Lakewood, New Jersey, USA) in RPMI
(Gibco BRL, Warrington, UK) for four hours at 37°C in humid-
ified air with 5% carbon dioxide. Dissociated cells were plated
in RPMI 1640 supplemented with 10% FCS (Gibco BRL,
Warrington, UK), 10 ml of 1 mmol/L HEPES (Gibco BRL,
Warrington, UK), penicillin (100 units/ml), streptomycin (100
units/ml), and fungizone (0.25 μg/ml) (all from Biosciences,
Co. Dublin, Ireland). The cells were incubated and grown to
confluence in T75 flasks (about 10 days) at 37°C in humidified
air with 5% carbon dioxide before being harvested with trypsin
and passaged. RASFs between the fourth and eighth pas-
sages were used for experiments.
Primary chondrocyte cell culture
Normal human articular cartilage was obtained from patients
undergoing surgery for traumatic fracture of the femoral neck,
each of whom had no history or radiological evidence of arthri-
tis. Chondrocytes were isolated from the tissue by sequential
proteolysis [32]. Cells were plated in DMEM supplemented
with 10% FCS, 10 ml of 1 mmol/L, penicillin (100 units/ml),
streptomycin (100 units/ml) and fungizone (0.25 μg/ml).
Chondrocytes were used for experiments up until the eighth
passage.
RASFC, cartilage and chondrocyte cultures
Cartilage explant cultures were prepared using 3 mm punch
biopsy specimens, thus ensuring that only full-depth cartilage
biopsy samples were used. RASFC and cartilage explants
were cultured in 96-well plates in serum-free RPMI 1640 sup-
plemented with 10% FCS, penicillin (100 units/ml), and strep-
tomycin (100 units/ml) in the presence of TNF-α (10 ng/ml),
OSM (10 ng/ml) and IL-17A (50 ng/ml) alone and in combina-
tion. Cartilage explants were cultured over a time course of 15
days, which has been demonstrated previously to be an opti-
mal time-point to examine proteoglycan depletion from carti-
lage sections [33,34]. As RASFCs are the primary cells that
invade cartilage, RASFC experiments were also performed
over a 15-day time course to examine if induction of MMPs in
response to IL-17A could be sustained over the same time
period. Culture supernatants were harvested every four days,
and wells were replenished with fresh medium containing
cytokine conditions that were identical to the medium used on
day 1. Following the culture period, supernatants were pooled
from each time point and stored at -80°C for analysis of
proMMP-1, proMMP-13, TIMP-1, MMP-2 and MMP-9. Carti-
lage and RASFC experiments were performed in duplicate.
Cartilage explants were paraffin embedded for immunohisto-
logical analysis.
Primary chondrocytes were cultured in 96-well plates in
serum-free DMEM supplemented with penicillin (100 units/
ml), and streptomycin (100 units/ml) for 24 hours in the pres-
ence of TNF-α (10 ng/ml), OSM (10 ng/ml) and IL-17A (50
ng/ml) alone and in combination. Chondrocyte experiments
were performed in duplicate.
Histological examination of human cartilage explants
Following the culture period, human cartilage explants were
removed and fixed overnight in 7% formaldehyde in PBS (pH
7.4) and embedded in wax. Five-micrometer sections were
stained with H&E and examined microscopically. For analysis
of proteoglycans, 5 μm sections were stained with Safranin O-
fast green and counterstained with haematoxylin [35].
Whole RA synovial tissue explants
An ex vivo RA ST explant model was established, as previously
described [36]. Each ST biopsy section was placed in a 96-
well plate in serum-free RPMI supplemented penicillin (100
units/ml), streptomycin (100 units/ml), and fungizone (0.25
μg/ml) for 24 hours at 37°C in air with 5% carbon dioxide.
Synovial explants were then stimulated (in triplicate) for 24
hours with TNF-α (10 ng/ml; R&D Systems, Europe, Abing-
don, Oxon, United Kingdom) and IL-17A (10 to 20 ng/ml; R&D
Systems, Europe, Abingdon, Oxon, United Kingdom). Follow-
ing incubation for 24 hours, biopsy wet weights are obtained.
The conditioned media was aspirated, collected and frozen at
-80°C until assayed for proMMP-1, MMP-2, MMP-9 and TIMP-
1 by ELISA and zymography. For Humira blockade experi-
ments, each ST biopsy section was placed in a 96-well plate
in full DMEM for 48 hours with Humira (10 μg/ml) or IgG con-
trol antibody (4 μg/ml). Following the incubation period,
biopsy wet weights were obtained. The conditioned media
was aspirated, collected and frozen at -80°. Supernatants
were assayed for IL-17A by an MSD assay as this has a sen-
sitivity of 0.4 pg/ml.Arthritis Research & Therapy    Vol 11 No 4    Moran et al.
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ProMMP-1, proMMP-13, pro-MMP-3, TIMP-1 and TIMP4 
quantification
ProMMP-1, proMMP-13 and TIMP-1 levels were quantified by
specific ELISA (R&D Systems Europe, Abingdon, Oxon,
United Kingdom). The ELISA minimum detectable doses were
0.021 ng/ml, 7.7 pg/ml, 0.009 ng/ml, 0.08 ng/ml and 4.91 pg/
ml. The ELISA standard ranges were 10 ng/ml to 0.156 ng/ml,
5000 pg/ml to 78 pg/ml, 0.002 ng/ml to 0.045 ng/ml, 10 ng/
ml to 0.156 ng/ml and 2.14 pg/ml to 10.0 pg/ml, respectively.
Gelatin zymography for MMP-2 and MMP-9
Culture supernatants were separated by electrophoresis
under nonreducing conditions by SDS-PAGE in 10% polyacr-
ylamide gels copolymerised with 1% gelatin. Gels were
washed vigorously twice for 25 minutes in 2.5% Triton X-100
to remove SDS, rinsed for 25 minutes in dH2O, then incubated
overnight in 50 mM Tris/NaCl, pH 7.5, 10 mM CaCl2 at 37°C.
Following overnight incubation gels were rinsed for five min-
utes in dH2O before addition of zymography stain (150 ml
dH2O, 75 ml isopropanol, 25 ml acetic acid, 0.6255 g Brilliant
Blue R). Gels were visualised using the UVP Bioimaging Auto-
Chemi system (UVP, Cambridge, UK).
Patients pre- and post-biologic therapy
A total of 38 patients were recruited from rheumatology outpa-
tient clinics at St. Vincent's University Hospital and were fol-
lowed up prospectively for one year. All patients had clinically
active disease, with 28-joint count Disease Activity Scores
(DAS28) of more than 3.2 points despite conventional dis-
ease-modifying anti-rheumatic drug therapy, and were offered
treatment with biologic agents. Patients who had previously
received biologic therapy were excluded from the study.
Changes in conventional therapy were permitted during bio-
logic therapy at the discretion of the patient's treating rheuma-
tologist; however, no changes in the disease-modifying anti-
rheumatic drug dosage were made during the study. Following
approval by the institutional ethics committee at St. Vincent's
University Hospital, all patients gave their fully informed written
consent prior to inclusion in the study. All 38 patients began
biologic therapy after their baseline assessment of disease
activity. Patients were evaluated before and at 1, 3 and 12
months after initiation of biologic therapy.
Blood samples were obtained and sera was separated and
stored at -80°C until used for biomarker analysis, and samples
were available for this study at baseline and three months.
Clinical evaluation at each assessment was performed using
the DAS28, and the modified Health Assessment Question-
naire [9]. The DAS28 response was analysed both by
changes in scores from baseline and by response categories
according to the European League Against Rheumatism
(EULAR) criteria [9]. A DAS28 response at three months was
defined as a reduction in the DAS28 score of 0.6 points or
more and a final DAS28 score of 5.1 points or less. A DAS28
nonresponse was defined as an improvement of less than 0.6
points or a final DAS28 score of more than 5.1 points. Patients
achieving clinical remission at six months were identified
according to EULAR criteria (DAS28 < 2.6 points) [9]. In addi-
tion, the patient's global assessment of his or her overall health
was recorded at each visit, using a visual analog scale of 0 to
100 mm, where 0 is the best and 100 is the worst score.
Serum was assessed for IL-17A, MMP-1, TIMP-1, MMP3,
TIMP-4, acute serum-amyloid A (A-SAA), the collagen degra-
dation markers C1, 2C and C2C and the synthesis markers
CS846 and CPII at baseline and three months post therapy.
Measurement of acute serum-amyloid A
A-SAA protein levels were measured using a sandwich
enzyme immunoassay (Biosource, London, UK). Standards
ranged from 9.4 to 300 ng/ml. The minimal detectable dose of
the assay was 5 ng/ml.
Quantification of IL-17A by MSD assay
Expression of IL-17A in synovial explant was assayed by MSD
assay. The assay standard range was 0.15 pg/ml to 10,000
pg/ml. The lowest limit of detection was 0.4 pg/ml.
Quantification of cartilage neoepitopes – C1, 2C, C2C, 
CS846 and CPII
The collagen degradation markers C1, 2C and C2C and the
synthesis markers CS846 and CPII were measured by com-
petitive immunoassay as per manufacturer's instructions (Ibex,
Montreal, Canada). The ELISA minimum detectable doses
were 0.03 μg/ml, 10 ng/ml, 20 ng/ml and 50 ng/ml. The ELISA
standard ranges were 0.03 μg/ml to 10 μg/ml, 10 ng/ml to 1
μg/ml, 20 ng/ml to 1000 ng/ml and 50 ng/ml to 2000 ng/ml,
respectively
Statistical analysis
Statistical analysis was performed using SPSS 11 for Win-
dows (SPSS, Chicago, IL, USA). Wilcoxon Rank and Mann
Whitney U statistical tests were used. P values less than 0.05
were considered significant.
Results
Expression of IL-17A in the inflammatory joint
IL-17A levels were detectabl e  i n  5 4 %  o f  S F  a n d  2 3 %  o f
serum. IL-17A serum levels were higher in patients with inflam-
matory arthritis compared with OA patients (24.3 ± 9.6 pg/ml
vs. 12.32 ± 12.32 pg/ml). Serum IL-17A levels were signifi-
cantly higher in patients with inflammatory arthritis compared
with healthy controls (P < 0.05; Figure 1a). Furthermore, levels
of IL-17A in SF were significantly higher than their matched
serum levels (Figure 1b). SF IL-17A levels were also higher in
inflammatory arthritis compared with OA (Figure 1c). High lev-
els of IL-17A expression were demonstrated in ST lysates in
both RA and PsA, markedly higher than OA ST (Figure 1d). No
significant difference was found between levels in RA and PsA
tissue. SF IL-17A levels were found to correlate directly with a
measure of disease activity – C-reactive protein (CRP) (n =Available online http://arthritis-research.com/content/11/4/R113
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43, r2 = 0.330, P < 0.05) and disease duration (n = 24, r2 =
0.470, P < 0.05). IL-17A was expressed in RA sublining, but
not OA or healthy control synovium (Figure 1e). IL-17A expres-
sion tended to be scattered throughout the sublining; how-
ever, in some RA patients we demonstrated an aggregate of
IL-17A positive cells (Figure 1e).
IL-17A modulates MMP production
RASFC MMP-1 production was significantly increased by IL-
17A (P < 0.015; Figure 2a) and for MMP-13 (P < 0.05; Figure
2b). Primary chondrocyte MMP-1 and MMP-13 expression
was also significantly up-regulated by IL-17A (P < 0.05; Figure
2b). IL-17A and OSM combined potentiated the effect on
MMP-1 and MMP-13 induction in both primary chondrocytes
and RASFC compared with baseline and either cytokine alone
(P < 0.05; Figures 2b, d). Similar effects were also observed
with TNF-α (data not shown). Although no major effect was
observed for MMP-2 activity in RASFCs, it was strongly upreg-
ulated by the combination of IL-17A/OSM in primary chondro-
cytes compared with either cytokine alone. (Figure 2e).
IL-17A potentiates effects of TNF-α and OSM on 
cartilage degradation
IL-17A upregulates MMP-1 production in human cartilage cul-
tures (Figure 3a); however, this did not reach significance.
OSM significantly upregulated MMP-1 production in cartilage
explants (P < 0.01). In combination IL-17A significantly poten-
tiated the effect of OSM on MMP-1 production compared with
basal (P < 0.01) and either cytokine alone (P < 0.05; Figure
3a). No significant effect was seen on TIMP-1 production (Fig-
ure 3b). The combination of IL-17A and OSM significantly
shifts the MMP-1: TIMP-1 ratio in favor of cartilage degrada-
Figure 1
Over-expression of IL-17A in the human inflamed joint Over-expression of IL-17A in the human inflamed joint. IL-17A expression was measured by ELISA in serum (SRM) (a) from patients with inflamma-
tory arthritis (IA; n = 40) vs. healthy controls (HC), (b) paired serums and synovial fluids (SF; n = 45), (c) synovial fluids from patients with inflamma-
tory arthritis (n = 49) vs. osteoarthritis (OA) and (d) rheumatoid arthritis (RA; n = 11), psoriatic arthritis (PsA; n = 11) and OA (n = 3) synovial tissue 
lysates. (e) IL-17A-producing cells are detected in RA but not OA or healthy control synovium (E).Arthritis Research & Therapy    Vol 11 No 4    Moran et al.
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tion compared with baseline and either cytokine alone (P <
0.01; Figure 3d). A similar effect was seen on the MMP-13/
TIMP-1 ratio in cartilage (P < 0.05; data not shown). Cartilage
MMP-13 production was also upregulated by IL-17A and TNF-
α alone, from basal of 8.34 ± 4.39 ng/ml to 14.47 ± 8.50 ng/
ml and 12.56 ± 4.6 ng/ml, respectively (Figure 3c); however,
this was not significant. The combination of IL-17A and TNFα
had a potentiation effect significantly up-regulating MMP-13
production (P < 0.01; Figure 3c). The MMP-13: TIMP-1 ratio
was also significantly shifted by the combination of TNF-α and
IL-17A compared with basal (P < 0.01) and either cytokine
alone (P < 0.05) (Figure 3d). Cartilage incubated with combi-
nations of TNF-α/IL-17A and OSM/IL-17A, demonstrated
almost complete proteoglycan depletion as shown by
Safranin-O staining whereas the cytokines alone showed only
a mild reduction (Figure 3e).
IL-17A stimulation alters MMP-1: TIMP-1 ratio in whole 
RA ST explants
RA ST explants (n = 11) were cultured in the presence of IL-
17A (10 ng/ml or 20 ng/ml) or TNF-α (10 ng/ml), nine showed
a response to stimulation with both IL-17A and TNF-α. MMP-
1 production by ST explants was increased 1.8 and 2.1 fold
by IL-17A (10 and 20 ng/ml) and 4.4 fold by TNF-α from basal
of 9202.64 ± 8806.31 ng/mg of tissue to 16,711.80 ±
15,535.07 ng/mg of tissue (P  < 0.05), 19,510.08 ±
18,261.87 ng/mg of tissue (P = 0.066) and 40,884.073 ±
3,5621.206 ng/mg of tissue (P < 0.01), respectively (Figure
4a). No significant effect was observed for TIMP-1 production
following stimulation with both concentrations of IL-17A or
TNF-α (Figure 4b). However, a significant shift in the MMP-1:
TIMP-1 ratio was demonstrated (P  < 0.01). Furthermore
increased expression of pro-MMP-9 and both the pro and
active forms of MMP-2 were demonstrated in response to IL-
17A stimulation (Figure 4d).
Regulation of IL-17A expression by biologic therapy
IL-17A protein levels were measured in a previously described
cohort of patients [9] undergoing biologic therapy by ELISA.
Baseline and three month serum samples of 38 patients were
assayed. At baseline, nine patients showed detectable levels
of IL-17A. Following three months of therapy, two patients
whom at baseline showed undetectable levels had detectable
levels of IL-17A. These 11 patients were categorised as the IL-
17A-positive group. The remaining 27 patients were negative
for IL-17A expression at both baseline and three months and
were categorised as the IL-17A-negative group, 70% of which
had a clinical response to anti-TNF-α therapy at three months.
Figure 2
Stimulation of RASFCs and chondrocytes with IL-17A alone and combined with TNF-α and OSM causing significant matrix turnover Stimulation of RASFCs and chondrocytes with IL-17A alone and combined with TNF-α and OSM causing significant matrix turnover. Primary syno-
vial fibroblasts (RASFCs; white bars) and chondrocytes (black bars) were cultured in the presence of IL-17A (50 ng/ml) alone and in combination 
with TNF-α (10 ng/ml) or oncostatin M (OSM; 10 ng/ml) for 15 days and 24 hours respectively. (a to d) Culture supernatants were analysed for the 
expression of matrix metalloproteinase (MMP)-1 and MMP-13 by ELISA. Values are the mean and standard error results from nine experiments 
(RASFCs) and five experiments (chondrocytes). * P < 0.05 versus baseline. (e) MMP-2 activity was examined by gelatin zymography in the culture 
supernatants.Available online http://arthritis-research.com/content/11/4/R113
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In the IL-17A-positive group, 82% showed a decrease in IL-
17A levels after three months of therapy, while 18% showed
an increase. Patients that showed a decrease post therapy
were also those patients that had been defined as clinical
responders, while those showing an increase post therapy
(dotted lines) were non-responders (Figure 5a). All but one of
these patients maintained this response to 12 months post
therapy. The change in IL-17A levels pre/post biologic therapy
strongly correlated with the change in CRP (r2 = 0.817, P <
0.01) and the change in A-SAA (r2 = 0.627, P < 0.05), mark-
ers of the acute phase response. When patients were catego-
rised into those with detectable IL-17A levels and those with
no detectable IL-17A levels, a significant difference in serum
matrix turnover markers was demonstrated. MMP-1 and MMP-
3 levels were significantly reduced in the IL-17A-negative
patients (P  < 0.05) compared with the IL-17A-positive
patients, which showed no significant change (data not
shown). The MMP-1/TIMP-1 ratios were higher in the IL-17A-
Figure 3
IL-17A in combination with TNF-α and OSM synergistically shifts the MMP-1: TIMP-1 and MMP-13: TIMP-1 ratios and drives cartilage destruction IL-17A in combination with TNF-α and OSM synergistically shifts the MMP-1: TIMP-1 and MMP-13: TIMP-1 ratios and drives cartilage destruction. 
Human cartilage explants were cultured in the presence of IL-17A (50 ng/ml) alone and in combination with TNF-α (10 ng/ml) or oncostatin M 
(OSM; 10 ng/ml). (a to d) Culture supernatants were analysed for the expression of matrix metalloproteinase (MMP)-1, MMP-13, and tissue inhibitor 
of metalloproteinase (TIMP)-1 by ELISA. Values are the mean and standard error results from nine experiments. * P < 0.05 versus baseline. Cartilage 
was formalin-fixed and embedded. (e) Proteoglycan staining was demonstrated by safranin O-fast green immunostaining.Arthritis Research & Therapy    Vol 11 No 4    Moran et al.
Page 8 of 12
(page number not for citation purposes)
negative patients compared with IL-17A-positive patients but
this was not significant (Figure 5b). A significant reduction was
demonstrated for the MMP-1/TIMP4, MMP3/TIMP1 and
MMP3/TIMP4 ratios in IL-17A-negative patients (all P < 0.05),
compared with IL-17A-positive patients where we demon-
strated no significant reduction in any of the MMP/TIMP ratio.
This demonstrates decreased matrix degradation three
months post therapy in those patients with no detectable IL-
17A levels (Figure 5b). Although there is no change from
baseline MMP/TIMP ratios pre/post anti-TNF-α therapy in the
IL-17A-positive patients, the levels of IL-17A were decreased
post therapy. This suggests that patients with detectable IL-
17A levels may sustain a higher MMP/TIMP ratio than those
that are negative; however, other complex regulatory proc-
esses may also be involved in regulating matrix turnover, pos-
sibly through interactions with IL-17A or independently.
Cartilage biomarkers were also measured in the IL-17A-nega-
tive and positive patients. There were no significant differ-
ences in the serum levels of C1, 2C, C2C and CPII pre/post
therapy in either group. However, CS846 a marker of prote-
oglycan synthesis was significantly higher in the IL-17A-posi-
tive patients compared with the IL-17A-negative group at both
baseline (262.5 ± 68.1 ng/ml vs. 158 ± 18.4 ng/ml) and three
months post therapy (246.2 ± 60 ng/ml vs. 159 ± 14.9 ng/ml;
P < 0.05). Finally, IL-17A production was measured in synovial
explants following incubation with Humira and IgG control
antibody. Levels of IL-17A were too low to be detected, or
were at the lower end of the standard curve and were not reli-
able.
Discussion
In this study we examined the expression of IL-17A in the
human inflammatory joint. An ex vivo RA ST explant model,
RASFCs, normal human cartilage and chondrocyte cultures
were used to investigate the mechanistic role of IL-17A, alone
and in combination, with TNF-α and OSM on matrix turnover
and cartilage proteoglycan release. The effect of biologics
therapy on IL-17A expression and matrix turnover was also
examined in vivo in a previously described cohort.
In this study we have shown high expression of IL-17A in ST
lysates with no significant difference between RA and PsA tis-
Figure 4
IL-17A significantly shifts the MMP-1: TIMP-1 ratio in rheumatoid arthritis synovial explant cultures IL-17A significantly shifts the MMP-1: TIMP-1 ratio in rheumatoid arthritis synovial explant cultures. Whole rheumatoid arthritis (RA) synovial tissue 
explants were serum-starved for 24 hours and incubated with TNF-α (10 ng/ml), IL-17A (10 ng/ml) or IL-17A (20 ng/ml) alone and in combination. 
(a to c) Levels of matrix metalloproteinase (MMP)-1 and tissue inhibitor of metalloproteinase (TIMP)-1 in culture media were measured by ELISA. 
Values are the mean and standard error results from seven experiments. * P < 0.05 versus baseline (Basal). (d) MMP-2 and -9 activity in the culture 
supernatants was assessed by gelatin zymography.Available online http://arthritis-research.com/content/11/4/R113
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sue. Furthermore, IL-17A expression was markedly higher in
RA and PsA ST compared with OA. Our results are consistent
with previous studies demonstrating increased IL-17A pro-
duction from RA patients compared with OA [13]; however,
our data differ as samples are from patients with early active
inflammation before commencing biologic therapy. We also
report significantly higher IL-17A levels in SF and serum from
inflammatory arthritis patients compared with OA and healthy
controls. SF levels of IL-17A were significantly higher than
matched serum suggesting that the cytokine is predominantly
produced locally in the inflamed joint. Although previous
reports showed elevated serum and SF IL-17A levels in RA
patients compared with healthy controls [37] these studies did
not examine matched serum/SF samples as performed in this
study. Interestingly, there was a strong correlation of SF IL-
17A levels with CRP and disease duration. This finding is not
surprising because previous animal model studies have sug-
gested IL-17A drives disease activity and is associated with
disease chronicity [27]. Furthermore, IL-17A is a potent
inducer of CRP from human smooth muscle cells and hepato-
cytes [38]. We also demonstrated IL-17A expression in RA
but not OA or healthy control synovium. IL-17A was expressed
in 70% of RA patients examined, which is consistent with pre-
vious reports [39].
A fine balance exists between active MMP and TIMP levels in
normal tissue and cartilage. In inflammatory conditions such as
RA, this balance shifts leading to an increase in the ratio of
active MMP: TIMP [40]. The effect of IL-17A on MMP expres-
sion was first examined in RASF and normal human chondro-
cyte cultures. IL-17A alone upregulated the expression of
MMP-1 and MMP-13 in both chondrocytes and RASFCs. IL-
17A combined with OSM synergistically upregulated MMP-1
production in both chondrocytes and RASFs. A similar effect
was observed for chondrocyte MMP-13 production with a less
potent effect on RASF MMP-13 production. IL-17A alone also
caused an increase in matrix turnover in chondrocytes as seen
by the increased MMP-9 activity. IL-17A combined with OSM
had an additive effect on matrix turnover as seen by the
increased MMP-9 activity compared with either cytokine
alone. Our results are consistent with previous studies show-
ing IL-17A induced MMP expression in human OA chondro-
cytes [41] and in RA synoviocytes [18]. In animal cells IL-17A
has been previously shown to act synergistically with TNF-α
and OSM in upregulating proinflammatory cytokine and chem-
okine expression and cartilage breakdown [18,42,43]. In this
study for the first time we have shown in human cells isolated
from patients with inflammatory arthritis that IL-17A combined
with OSM synergistically upregulates the expression of MMP-
1, MMP-2, MMP-9 and MMP-13 in both chondrocytes and
RASFs.
We also showed for the first time in human cartilage explants
and a human ex vivo synovial explant culture model, that IL-
Figure 5
IL-17A expression is modulated pre/post biologic therapy IL-17A expression is modulated pre/post biologic therapy. Baseline and three months serum samples from 38 patients were analysed using IL-17A 
ELISA. Eleven of these patients showed detectable levels of IL-17A. (a) Data shown are of these 11 patients. (b) Matrix metalloproteinase (MMP)/
tissue inhibitor of metalloproteinase (TIMP) ratios are significantly reduced in IL-17A-negative patients three months following biologic therapy.Arthritis Research & Therapy    Vol 11 No 4    Moran et al.
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17A regulates MMP production and cartilage degradation,
which is supported by previous animal studies [18,19]. IL-17A
alone significantly shifted the MMP-1: TIMP-1 ratio in favour of
a destructive pattern. Significant matrix turnover was also
demonstrated by increased MMP-2 and MMP-9 activity in
response to IL-17A stimulation. Mild proteoglycan depletion
was observed in response to IL-17A stimulation visualised by
loss of safranin-O staining. However, when IL-17A was com-
bined with other key pro-inflammatory cytokines it significantly
potentiated the effect of TNF-α and OSM on MMP-1 and
MMP-13 production. This had a profound effect on the MMP/
TIMP ratios, which shifted dramatically in favour of matrix deg-
radation. Furthermore, when human cartilage explants were
incubated with IL-17A, TNF or OSM alone, mild proteoglycan
depletion was observed; however, when IL-17A was com-
bined with OSM or TNF, near complete proteoglycan deple-
tion compared with either cytokine alone was demonstrated.
These results suggest that in the inflamed joint environment,
which has a complex milieu of pro-inflammatory cytokines, that
in addition to exerting its effects alone, IL-17A appears to have
an important role in dramatically potentiating the destructive
effects of other pro-inflammatory cytokines, such as TNF-α
and OSM. Increased MMP expression has been observed in
human chondrocytes in response to IL-17A stimulation [41]
but no previous studies has examined its effect on RA whole
tissue synovial explants or human cartilage explants. Whole
tissue explant cultures more closely mimic the joint environ-
ment, as the architecture, cell-cell interactions and ECM
remains intact, which can result in expression of genes and
proteins to stimuli that differ from monolayer cultures. Thus the
combination of mono-culture and whole tissue explant culture
in this study dissects the cellular responses such as MMP
expression to specific stimuli more effectively [44].
Finally, we examined IL-17A and MMP/TIMP production in
patients pre/post biologic therapy on IL-17A. We demonstrate
for the first time that IL-17A serum levels are reduced in inflam-
matory arthritis patients following TNF blockade in vivo. We
show that serum IL-17A levels are modulated by biologic ther-
apy with 80% of patients showing a decrease in IL-17A three
months post therapy. Significantly, this reduction was demon-
strated in patients who showed a clinical response, while non-
responders showed an increase. Change in IL-17A also corre-
lated with change in CRP and A-SAA, markers of systemic
inflammation. Previous studies have shown synovial mem-
brane mRNA levels of IL-17A may predict joint damage pro-
gression in RA [45] and IL-17A serum levels correlate with
disease severity in psoriasis patients [46]. IL-23 (a key factor
in Th17 differentiation) has been genetically linked to
increased susceptibility to psoriasis [46,47]. Furthermore, dis-
ease resolution in psoriasis patients following TNF blockade
correlates with reduced Th17 responses [48].
Furthermore, we demonstrate a significant difference in MMP/
TIMP ratios from baseline to three months post therapy in IL-
17A-negative patients, with no significant difference in IL-17A-
positive patients. However, interpretation of this data is com-
plex. IL-17A-positive patients may exhibit a sustained stimula-
tion of MMPs; however, as the IL-17A levels do reduce after
three months in most patients, it may suggest other pro-inflam-
matory mediators such as TNF-α, IL-1β and OSM are driving
MMP expression. Indeed, this is supported by our in vitro data
and the results of other studies [34,42] demonstrating IL-17A
acts in synergy with TNF-α, OSM and other cytokines leading
to increased MMP activity.
Numerous studies have associated MMP serum levels in par-
ticular MMP-3 levels to disease activity and radiographic pro-
gression [49-55]. SNPs in the IL-17A gene have been
associated with radiographic progression [56]. Furthermore,
one of the main drivers of IL-17A production, IL-23, is present
in higher levels in patients with bone erosions than those with-
out erosions [57]. The observation of higher CS846 levels in
IL-17A-positive sera may be relevant radiographically.
Increased serum levels of CS846 are an indicator of increased
turnover of newly formed matrix, as part of an attempt to repair
cartilage degradation [58]. Furthermore, patients with rapid
radiographic progression have been shown to have higher
CS846 epitope levels than slow progressors [59].
Overexpression of IL-17A by injection or gene expression sig-
nificantly increased inflammatory infiltrate and resulted in
extensive joint destruction [22,60]. Furthermore, in studies
that blocked IL-17A or in IL-17R-/- mice reduced inflammation
and bone damage was observed [61,62]. In murine studies IL-
17A has been shown to act independently of TNF-α [27,28].
A number of studies have shown TNF inhibition has no effect
on IL-17A or IL-23 expression [63-65]. Furthermore, the IL-
17A/TNF-α ratio pre-treatment was shown to be lower in
responders to anti-TNF treatment [29]. This data and previous
studies suggest that IL-17A synergises with other pro-inflam-
matory cytokines but can also enhance inflammation and
destruction independently and would propose IL-17A as a
potential target in the treatment of RA.
Conclusions
In this study we have shown that IL-17A is highly expressed in
the inflammatory joint and drives disease activity, implicating it
as a key cytokine and potential therapeutic target. We have
shown that IL-17A not only drives the proinflammatory
response but also enhances the effect of TNFα and OSM, pro-
moting increased destruction in the RA joint. Finally, we dem-
onstrate that IL-17A levels are modulated in vivo, following
anti-TNF therapy, and may reflect changes in matrix turnover.
Competing interests
The authors declare that they have no competing interests.Available online http://arthritis-research.com/content/11/4/R113
Page 11 of 12
(page number not for citation purposes)
Authors' contributions
EM performed most of the experiments, data analysis and
manuscript preparation. RM collected the clinical cohort and
participated in study design and data analysis. JMcC, MC and
OS performed some experiments. BB and OF participated in
study design and data analysis. UF and DV conceived the
study and developed the study design, performed data analy-
sis and prepared the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by the Health Research Board, Ireland.
References
1. Arend WP, Dayer J: Cytokines and cytokine inhibitors or antag-
onists in rheumatoid arthritis.  Arthritis Rheum 1990,
33:305-315.
2. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z: Angiogen-
esis and chemokines in rheumatoid arthritis and other sys-
temic inflammatory rheumatic diseases.  J Cell Mol Med 2002,
6:357-376.
3. Szekanecz Z, Kim J, Koch AE: Chemokines and chemokine
receptors in rheumatoid arthritis.  Semin Immunol 2003,
15:15-21.
4. Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM:
Molecular therapeutic targets in rheumatoid arthritis.  Expert
Rev Mol Med 2005, 7:1-20.
5. Poole AR, Alini M, Hollander A: Cellular biology of cartilage deg-
radation.  I n  Mechanisms and models in rheumatoid arthritis
Edited by: Henderson B, Edwards JC, Pettigher ER. London: Aca-
demic Press; 1995:163-204. 
6. Heijde DM Van der: How to read radiographs according to the
Sharp/van der Heijde method [corrected and republished in J
Rheumatol 2000, 27:261–263].  J Rheumatol 1999, 26:743.
7. Drossaers-Bakker KW, De Buck M, Van Zeben D, Zwinderman
AH, Breedveld FC, Hazes JMW: Long-term course and outcome
of functional capacity in rheumatoid arthritis: the effect of dis-
ease activity and radiologic damage over time.  Arthritis Rheum
1999, 42:1854-1860.
8. Poole AR: Can serum biomarker assays measure the progres-
sion of cartilage degeneration in osteoarthritis?  Arthritis
Rheum 2002, 46:2549-2552.
9. Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole
AR, Fearon U, Veale DJ: Early changes in serum type ii collagen
biomarkers predict radiographic progression at one year in
inflammatory arthritis patients after biologic therapy.  Arthritis
Rheum 2007, 56:2919-2928.
10. Kolls JK, Lindén A: Interleukin-17 family members and inflam-
mation.  Immunity 2004, 21:467-476.
11. Zhou Y, Toh M-L, Zrioual S, Miossec P: IL-17A versus IL-17F
induced intracellular signal transduction pathways and modu-
lation by IL-17RA and IL-17RC RNA interference in AGS gastric
adenocarcinoma cells.  Cytokine 2007, 38:157-164.
12. Mills KHG: Induction, function and regulation of IL-17-produc-
ing T cells.  Eur J Immunol 2008, 38:2636-2649.
13. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L,
Miossec P: Human interleukin-17: A T cell-derived proinflam-
matory cytokine produced by the rheumatoid synovium.
Arthritis Rheum 1999, 42:963-970.
14. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama
S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T:
IL-17 in synovial fluids from patients with rheumatoid arthritis
is a potent stimulator of osteoclastogenesis.  J Clin Invest
1999, 103:1345-1352.
15. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S,
Maat C, Pin J, Garrone P, Garcia E, Saeland S, Blanchard D, Gail-
lard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J,
Lebecque S: T cell interleukin-17 induces stromal cells to pro-
duce proinflammatory and hematopoietic cytokines.  J Exp
Med 1996, 183:2593-2603.
16. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y,
Zhang M, Mineau F, Pelletier JP: IL-17 Stimulates the production
and expression of proinflammatory cytokines, IL-b and TNF-a
by human macrophages.  J Immunol 1998, 160:3513-3521.
17. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL,
Comeau MR, Cohen JI, Spriggs MK: Herpesvirus Saimiri
encodes a new cytokine, IL-17, which binds to a novel cytokine
receptor.  Immunity 1995, 3:811-821.
18. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec
P: Contribution of Interleukin-17 to synovium matrix destruc-
tion in rheumatoid arthritis.  Cytokine 2000, 12:1092-1099.
19. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan
AD:  Interleukin 17 induces cartilage collagen breakdown:
novel synergistic effects in combination with proinflammatory
cytokines.  Ann Rheum Dis 2002, 61:704-713.
20. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama
S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T:
IL-17 in synovial fluids from patients with rheumatoid arthritis
is a potent stimulator of osteoclastogenesis.  J Clin Invest
1999, 103:1345-1352.
21. Berg WB van den, van Lent PL, Joosten LAB, Abdollahi-Roodsaz
S, Koenders MI: Amplifying elements of arthritis and joint
destruction.  Ann Rheum Dis 2007, 66:iii45-48.
22. Chabaud M, Lubberts E, Joosten L, Berg W van den, Miossec P:
IL-17 derived from juxta-articular bone and synovium contrib-
utes to joint degradation in rheumatoid arthritis.  Arthritis Res
2001, 3:168-177.
23. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls
J, van den Berg WB: Overexpression of IL-17 in the knee joint
of collagen type II immunized mice promotes collagen arthritis
and aggravates joint destruction.  Inflamm Res 2002,
51:102-104.
24. Lubberts E, Joosten LAB, Chabaud M, Bersselaar L van den,
Oppers B, Coenen-de Roo CJJ, Richards CD, Miossec P, Berg
WB van den: IL-4 gene therapy for collagen arthritis sup-
presses synovial IL-17 and osteoprotegerin ligand and pre-
vents bone erosion.  J Clin Invest 2000, 105:1697-1710.
25. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D: Prostaglandin
E2 exacerbates collagen-induced arthritis in mice through the
inflammatory interleukin-23/interleukin-17 axis.  Arthritis
Rheum 2007, 56:2608-2619.
26. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y,
Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takay-
anagi H: Th17 functions as an osteoclastogenic helper T cell
subset that links T cell activation and bone destruction.  J Exp
Med 2006, 203:2673-2682.
27. Koenders MI, Lubberts E, Loo FAJ van de, Oppers-Walgreen B,
Bersselaar L van den, Helsen MM, Kolls JK, Di Padova FE, Joosten
LAB, Berg WB van den: Interleukin-17 Acts Independently of
TNF-a under Arthritic Conditions.  J Immunol 2006,
176:6262-6269.
28. Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen
MM, Bersselaar LA van den, Oppers-Walgreen B, Koenders MI,
Berg WB van den: T cell dependence of chronic destructive
murine arthritis induced by repeated local activation of toll-like
receptor-driven pathways: crucial role of both interleukin-
1beta and interleukin-17.  Arthritis Rheum 2008, 58:98-108.
29. Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M,
Goto D, Matsumoto I, Ito S, Suguro T, Sumida T: Interleukin-17
gene expression in patients with rheumatoid arthritis.  Mod
Rheumatol 2008, 18:15-22.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr,
Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT,
Wilder RL, Hunder GG: The american rheumatism association
1987 revised criteria for the classification of rheumatoid arthri-
tis.  Arthritis Rheum 1988, 31:315-324.
31. Veale DJ: The role of arthroscopy in early arthritis [review].  Clin
Exp Rheumatol 1999, 17:37-38.
32. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF,
Spaull JR, Goldring MB, Koshy PJ, Rowan AD, Shingleton WD:
The role of oncostatin M in animal and human connective tis-
sue collagen turnover and its localization within the rheuma-
toid joint.  Arthritis Rheum 1998, 41:1760-1771.
33. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR,
FitzGerald O, Bresnihan B, Veale DJ: Oncostatin M induces ang-
iogenesis and cartilage degradation in rheumatoid arthritis
synovial tissue and human cartilage cocultures.  Arthritis
Rheum 2006, 54:3152-3162.Arthritis Research & Therapy    Vol 11 No 4    Moran et al.
Page 12 of 12
(page number not for citation purposes)
34. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan
AD:  Interleukin 17 induces cartilage collagen breakdown:
novel synergistic effects in combination with proinflammatory
cytokine.  Ann Rheum Dis 2002, 61:704-713.
35. Hui W, Rowan AD, Richards CD, Cawston TE: Oncostatin M in
combination with tumor necrosis factor alpha induces carti-
lage damage and matrix metalloproteinase expression in vitro
and in vivo.  Arthritis Rheum 2003, 48:3404-3418.
36. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR,
FitzGerald O, Bresnihan B, Veale DJ: Oncostatin M induces ang-
iogenesis and cartilage degradation in rheumatoid arthritis
synovial tissue and human cartilage cocultures.  Arthritis
Rheum 2006, 54:3152-3162.
37. Cho ML, Yoon CH, Hwang SY, Park MK, Min SY, Lee SH, Park
SH, Kim HY: Effector function of type II collagen-stimulated T
cells from rheumatoid arthritis patients: Cross-talk between T
cells and synovial fibroblasts.  Arthritis Rheum 2004,
50:776-784.
38. Patel DN, King CA, Bailey SR, Holt JH, Venkatachalam K, Agrawal
A, Valente AJ, Chandrasekar B: Interleukin-17 stimulates C-
reactive protein expression in hepatocytes and smooth mus-
cle cells via p38 MAPK and ERK1/2-dependent NF-kappa B
and C/EBPbeta activation.  J Biol Chem 2007,
282:27229-27238.
39. Joosten LA, Radstake TR, Lubberts E, Bersselaar LA van den, van
Riel PL, van Lent PL, Barrera P, Berg WB van den: Association of
interleukin-18 expression with enhanced levels of both inter-
leukin-1 and tumor necrosis factor alpha in knee synovial tis-
sue of patients with rheumatoid arthritis.  Arthritis Rheum 2003,
48:339-347.
40. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole
AR:  Relationships of matrix metalloproteinases and their
inhibitors to cartilage proteoglycan and collagen turnover and
inflammation as revealed by analyses of synovial fluids from
patients with rheumatoid arthritis.  Arthritis Rheum 2001,
44:2503-2511.
41. Benderdour M, Tardif G, Pelletier J, Di Battista JA, Reboul P,
Ranger P, Martel-Pelletier J: Interleukin 17 (IL-17) induces colla-
genase-3 production in human osteoarthritic chondrocytes via
AP-1 dependent activation: differential activation of AP-1
members by IL-17 and IL-1β.  J Rheumatol 2002,
29:1262-1272.
42. Van Bezooijen RL, Wee-Pals L Van der, Papapoulos SE, Lowik
CWGM: Interleukin 17 synergises with tumour necrosis factor
a to induce cartilage destruction in vitro.  Ann Rheum Dis 2002,
61:870-876.
43. Chabaud M, Fossiez F, Taupin J-L, Miossec P: Enhancing effect
of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor
production by rheumatoid arthritis synoviocytes and its regu-
lation by Th2 cytokines.  J Immunol 1998, 161:409-414.
44. Mott JD, Werb Z: Regulation of matrix biology by matrix metal-
loproteinases.  Curr Opin Cell Biol 2004, 16:558-564.
45. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee
CS, Shnier R, Portek IJ: Synovial membrane cytokine expres-
sion is predictive of joint damage progression in rheumatoid
arthritis: A two-year prospective study (the DAMAGE study
cohort).  Arthritis Rheum 2006, 54:1122-1131.
46. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Cha-
mian F, Dhodapkar M, Krueger JG: Increased expression of
interleukin 23 p19 and p40 in lesional skin of patients with
psoriasis vulgaris.  J Exp Med 2004, 199:125-130.
47. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM: In vitro
and in situ expression of IL-23 by keratinocytes in healthy skin
and psoriasis lesions: enhanced expression in psoriatic skin.
J Immunol 2006, 176:1908-1915.
48. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-
Fariñas M, Fuentes-Duculan J, Novitskaya I, Khatcherian A, Bluth
MJ, Lowes MA, Krueger JG: Amelioration of epidermal hyper-
plasia by TNF inhibition is associated with reduced Th17
responses.  J Exp Med 2007, 204:3183-3194.
49. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S,
Saxne T, Robins S, Griffiths I: Biomarkers predict radiographic
progression in early rheumatoid arthritis and perform well
compared with traditional markers.  Arthritis Rheum 2007,
56:3236-3247.
50. Green MJ, Gough AKS, Devlin J, Smith J, Astin P, Taylor D, Emery
P: Serum MMP-3 and MMP-1 and progression of joint damage
in early rheumatoid arthritis.  Rheumatology 2003, 42:83-88.
51. Mattey DL, Nixon NB, Dawes PT, Ollier WE, Hajeer AH: Associa-
tion of matrix metalloproteinase 3 promoter genotype with
disease outcome in rheumatoid arthritis.  Genes Immun 2004,
5:147-149.
52. Jensen TKM, Hansen M, Jensen KE, Skjødt H, Hyldstrup L, Danisit
TIRA Group: Connective tissue metabolism in patients with
unclassified polyarthritis and early rheumatoid arthritis. Rela-
tionship to disease activity, bone mineral density, and radio-
graphic outcome.  J Rheumatol 2004, 31:1698.
53. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M,
Mielants H, Tempel H van der, Poole AR, Wang N, Heijde D van
der: Serum matrix metalloproteinase 3 is an independent pre-
dictor of structural damage progression in patients with anky-
losing spondylitis.  Arthritis Rheum 2007, 56:1846-1853.
54. Fiedorczyk MKP, Sierakowski S, Domyslawska I, Chwiecko J: Cor-
relations between serum matrix metalloproteinase (MMP-1,
MMP-3, MMP-9, MMP-13) concentrations and markers of dis-
ease activity in early rheumatoid arthritis.  Przegl Lek 2005,
62:1321-1324.
55. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-
Ihle E, Franz J, Burmester GR, Jung K: Circulating levels of matrix
metalloproteinases MMP-3 and MMP-1, tissue inhibitor of
metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex
in rheumatic disease. Correlation with clinical activity of rheu-
matoid arthritis versus other surrogate markers.  Rheumatol-
ogy 1999, 26:251-258.
56. Furuya T, Hakoda M, Ichikawa N, Higami K, Nanke Y, Yago T,
Kamatani N, Kotake S: Associations between HLA-DRB1, RANK,
RANKL, OPG, and IL-17 genotypes and disease severity phe-
notypes in Japanese patients with early rheumatoid arthritis.
Clin Rheumatol 2007, 26:2137-2141.
57. Kim H-R, Kim H-S, Park M-K, Cho M-L, Lee S-H, Kim H-Y: The
clinical role of IL-23p19 in patients with rheumatoid arthritis.
Scand J Rheumatol 2007, 36:259-264.
58. Rizkalla G, Reiner A, Bogoch E, Poole AR: Studies of the articular
cartilage proteoglycan aggrecan in health and osteoarthritis.
Evidence for molecular heterogeneity and extensive molecu-
lar changes in disease.  J Clin Invest 1992, 90:2268-2277.
59. Verstappen S, Poole A, Ionescu M, King L, Abrahamowicz M, Hof-
man D, Bijlsma J, Lafeber F, (SRU) tURACSg: Radiographic joint
damage in rheumatoid arthritis is associated with differences
in cartilage turnover and can be predicted by serum biomark-
ers: an evaluation from 1 to 4 years after diagnosis.  Arthritis
Res Ther 2006, 8:R31.
60. Lubberts E, Joosten LAB, Oppers B, Bersselaar L van den,
Coenen-de Roo CJJ, Kolls JK, Schwarzenberger P, Loo FAJ van
de, Berg WB van den: IL-1-Independent Role of IL-17 in Syno-
vial Inflammation and Joint Destruction During Collagen-
Induced Arthritis.  J Immunol 2001, 167:1004-1013.
61. Koenders MI, Kolls JK, Oppers-Walgreen B, Bersselaar L van den,
Joosten LA, Schurr JR, Schwarzenberger P, Berg WB van den,
Lubberts E: Interleukin-17 receptor deficiency results in
impaired synovial expression of interleukin-1 and matrix met-
alloproteinases 3, 9, and 13 and prevents cartilage destruction
during chronic reactivated streptococcal cell wall-induced
arthritis.  Arthritis Rheum 2005, 52:3239-3247.
62. Lubberts E, Joosten LA, Loo FA van de, Gersselaar LA van den,
Berg WB van den: Reduction of interleukin-17-induced inhibi-
tion of chondrocyte proteoglycan synthesis in intact murine
articular cartilage by interleukin-4.  Arthritis Rheum 2000,
43:1300-1306.
63. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Wil-
liams RO: Blockade of tumor necrosis factor in collagen-
induced arthritis reveals a novel immunoregulatory pathway
for Th1 and Th17 cell.  J Exp Med 2008, 205:2491-2497.
64. Wendling D, Cedoz JP, Racadot E: Serum and synovial fluid lev-
els of p40 IL12/23 in spondyloarthropathy patients.  Clin Rheu-
matol 2008, 28:187-190.
6 5 . K a g e y a m a  Y ,  T a k a h a s h i  M ,  T o r i k a i  E ,  S u z u k i  M ,  I c h i k a w a  T ,
Nagafusa T, Koide Y, Nagano A: Treatment with anti-TNF-anti-
body infliximab reduces serum IL-15 levels in patients with
rheumatoid arthritis.  Clin Rheumatol 2007, 26:505-509.